Skip to main content

Daniel Ferry

Analyst

LifeSci Advisors

Equibles does not estimate personal net worth.

About Daniel Ferry

Daniel Ferry is recorded as Analyst at LifeSci Advisors and Head of Investor Relations at Praxis Precision Medicines, Inc. (PRAX). Daniel Ferry has spoken on 12 earnings calls across 4 companies, most recently for Praxis Precision Medicines, Inc. on August 6, 2026. Those appearances were for CorMedix Inc. (CRMD), X4 Pharmaceuticals, Inc (XFOR), Praxis Precision Medicines, Inc. (PRAX) and Mineralys Therapeutics, Inc. (MLYS). CorMedix Inc. is classified in the Biotechnology industry within the Healthcare sector. Praxis Precision Medicines, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Daniel Ferry spoke on are classified in the Healthcare sector. Other leadership on record at CorMedix Inc. includes Joseph Todisco (CEO, Chairman and Board Member), Matt David, M.D. (CEO), Matthew David, M.D. (CEO) and 7 others.

Daniel Ferry on recent calls

“Good morning, and welcome to the Praxis Precision Medicine's second quarter 2026 financial results and business update conference call.”
Head of Investor Relations, Praxis Precision Medicines Second Quarter 2026 Financial Results Conference Call ·
“Good morning, and welcome to the CorMedix First Quarter 2026 Earnings and Corporate Update Conference Call. Leading the call today is Joe Todisco, Chairman and Chief Executive Officer of CorMedix.”
Head of Investor Relations, CorMedix Inc. Q1 FY2026 Earnings Call ·
“Good morning, and welcome to the CorMedix Third Quarter 2025 Earnings and Corporate Update Conference Call. Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix; and he is joined by Liz Hurlburt, EVP and Chief Operating Officer; and Susan Blum, EVP and Chief Financial Officer.”
Analyst — LifeSci Advisors, CorMedix Inc. Q3 FY2025 Earnings Call ·
“I would like to welcome everyone joining us today for our third quarter 2025 conference call. Earlier this afternoon, we issued a press release providing our third quarter 2025 financial results and business updates.”
Host, Mineralys Therapeutics, Inc. Q3 FY2025 Earnings Call ·
“Thank you for joining us today for the special earnings call during which X4 will focus on providing a business update and, importantly, data and results from its now completed Phase II study of mavorixafor in chronic neutropenia.”
Host, X4 Pharmaceuticals, Inc Q3 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at CorMedix Inc.

Leadership on record at Praxis Precision Medicines, Inc.

Recent activity